Form 4: Sangamo Therapeutics Executive Reports Stock Transactions Following RSU Vesting
SEC Form 4 Filing
Nathalie Dubois-Stringfellow, SVP-Chief Development Officer at Sangamo Therapeutics, reports disposition of shares to cover tax obligations upon RSU vesting, while still holding a significant number of shares.
Summary
- Nathalie Dubois-Stringfellow, SVP-Chief Development Officer of Sangamo Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
- The reported transactions involve the disposition of common stock to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).
- On August 24, 2024, 1,787 shares were disposed of at a price of $0.86 per share for tax withholding purposes.
- On August 25, 2024, 1,508 shares were disposed of at a price of $0.86 per share for tax withholding purposes.
- Following these transactions, Dubois-Stringfellow beneficially owns 844,598 shares of Sangamo Therapeutics common stock.
- The remaining RSUs will continue to vest in quarterly installments through February 2026, subject to continuous service.
Sentiment
Score: 6
Explanation: The document is a routine disclosure of stock transactions related to RSU vesting. While the disposition of shares might be perceived negatively, it's primarily for tax purposes and doesn't necessarily reflect a lack of confidence in the company. The executive still holds a significant number of shares.
Positives
- The executive's continued holding of a significant number of shares (844,598) indicates confidence in the company's future.
- The vesting of RSUs incentivizes the executive to remain with the company and contribute to its success.
- The executive also participates in the Employee Stock Purchase Plan, further aligning her interests with those of shareholders.
Future Outlook
The executive's remaining RSU grants will continue to vest in quarterly installments through February 2026, contingent upon continuous service.
Industry Context
Form 4 filings are routine disclosures for publicly traded companies, providing transparency into the trading activities of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.
Comparison to Industry Standards
- Executive compensation packages often include RSUs to align management's interests with those of shareholders.
- Tax withholding upon RSU vesting is a standard practice across publicly traded companies.
- The vesting schedules and terms of the RSUs are typical for executive compensation plans in the biotechnology industry.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders, as they are related to tax obligations and do not represent a significant change in the executive's overall holdings.
- Shareholders may view the continued vesting of RSUs as a positive sign, as it incentivizes the executive to remain with the company.
Key Dates
| Date | Description |
|---|---|
| February 25, 2022 | Date of RSU grant that will vest in successive equal quarterly installments through February 25, 2025 |
| February 24, 2023 | Date of RSU grant that will vest in successive equal quarterly installments through February 24, 2026 |
| January 22, 2024 | Date of RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter |
| May 31, 2024 | Date of acquisition of 5,000 shares under the Issuer's 2020 Employee Stock Purchase Plan |
| August 23, 2024 | Issuer's closing stock price of $0.86/share used for tax withholding |
| August 24, 2024 | Date of transaction where 1,787 shares were disposed of for tax withholding. |
| August 25, 2024 | Date of transaction where 1,508 shares were disposed of for tax withholding. |
| August 27, 2024 | Date of signature of the Form 4 filing. |
| February 25, 2025 | End date of vesting for the February 25, 2022 RSU grant. |
| February 24, 2026 | End date of vesting for the February 24, 2023 RSU grant. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.